Parminder Raina, PhD; Pasqualina L. Santaguida, PhD; Christopher Patterson, MD
Potential Financial Conflicts of Interest:Honoraria: P. Santaguida (American College of Physicians).
Raina P., Santaguida P., Patterson C.; The Importance of Measuring Executive Function When Studying the Effects of Cognition-Enhancing Agents. Ann Intern Med. 2008;149:359-360. doi: 10.7326/0003-4819-149-5-200809020-00017
Download citation file:
Published: Ann Intern Med. 2008;149(5):359-360.
We thank Dr. Rockwood for his thoughtful and perceptive response to our review. We completely agree that aggregate scores on instruments that do not measure executive function may fail to capture useful improvements in individuals receiving cholinesterase inhibitors or other cognition-enhancing agents. Of the many attempts to isolate meaningful individual responses to treatment, goal attainment scaling is among the most sensitive and robust. Although “listening to patients” is not always a means of determining outcome and is rarely quantified in as rigorous a manner as advocated by Dr. Rockwood, we share his enthusiasm for it, the most basic and satisfying element of clinical care.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only